# Phase 2 Dose Finding sPIF in Patients With High Panel Reactive Antibodies

> **NCT03593421** · PHASE2 · WITHDRAWN · sponsor: **Christopher O'Brien, MD**

## Conditions studied

- Panel Reactive Antibodies

## Interventions

- **DRUG:** synthetic PreImplantation Factor

## Key facts

- **NCT ID:** NCT03593421
- **Lead sponsor:** Christopher O'Brien, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** BioInceptdecided not to pursue this drug target at this time.
- **Last updated:** 2019-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03593421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03593421, "Phase 2 Dose Finding sPIF in Patients With High Panel Reactive Antibodies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03593421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*